GLP1R and metabolic dysfunction-associated steatotic liver disease: The glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 agonist could be used not only for glucose metabolism control but also for NAFLD treatment, as this combination has synergic effects, promotes lipogenesis and weight loss [180].